Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory strategy aimed at accelerating the development of low-dose (Z)-endoxifen for breast cancer risk reduction. An update on the outcome of this meeting is expected by year-end 2025.

Science Significance

(Z)-Endoxifen is a highly potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity even in tumors resistant to existing endocrine therapies. Unlike tamoxifen, it bypasses CYP2D6 metabolism variability, allowing for faster, more predictable therapeutic exposure. Clinical studies have shown it can achieve target drug concentrations within hours, compared to weeks for tamoxifen.

Regulatory Significance

Atossa engaged leading FDA law and regulatory experts who concluded that existing evidence could support a faster approval pathway for breast cancer risk-reduction. The requested Type C meeting will seek FDA guidance on requirements to complete a New Drug Application (NDA). A favorable outcome could shorten timelines by years and save tens of millions in clinical trial costs.

Business Significance

Advertisement

cGxPJobs Banner

Atossa reported $57.9 million in cash and no debt as of June 30, 2025. The potential market for low-dose (Z)-endoxifen is substantial, with an estimated 1.6 to 2.1 million annual tamoxifen prescriptions in the U.S. alone, and millions of women currently using endocrine therapy. Atossa estimates a multi-billion-dollar opportunity if (Z)-endoxifen demonstrates superiority in tolerability and efficacy over tamoxifen and aromatase inhibitors.

Patients’ Significance

Millions of women at risk of breast cancer face treatment challenges:

  • Up to 20% of tamoxifen patients fail to achieve therapeutic drug levels.
  • Over 30% discontinue aromatase inhibitors due to painful side effects.

(Z)-Endoxifen’s predictable metabolism, faster onset, and improved tolerability could reduce recurrence rates and expand prevention options for high-risk women, DCIS patients, and those with prior breast cancer.

Policy Significance

This strategy aligns with FDA’s Project Optimus initiative, which emphasizes optimized dose selection to improve patient outcomes. A successful regulatory path could also support cost-efficient oncology innovation, influencing future policy for preventive cancer therapies.

Transaction Highlights

In June 2025, Atossa engaged an internationally recognized FDA law firm and regulatory experts to review extensive (Z)-endoxifen data and published literature. Their evaluation recommended promptly scheduling a Type C FDA meeting to discuss accelerated approval pathways. Atossa has now filed this request, with a shareholder update expected by year-end 2025. A favorable outcome could reduce approval timelines by several years, significantly lowering development costs.

Source: Atossa Therapeutics Inc. Press Release